Weber Capital Management LLC ADV Buys New Holdings in AngioDynamics, Inc. $ANGO

Weber Capital Management LLC ADV purchased a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the 2nd quarter, Holdings Channel reports. The fund purchased 1,356,602 shares of the medical instruments supplier’s stock, valued at approximately $17,649,392,000. AngioDynamics accounts for about 15.0% of Weber Capital Management LLC ADV’s holdings, making the stock its 4th largest holding.

Other institutional investors have also added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new position in AngioDynamics in the 2nd quarter valued at $1,578,000. Globeflex Capital L P acquired a new stake in AngioDynamics during the second quarter worth about $1,355,000. Ieq Capital LLC bought a new position in AngioDynamics in the 2nd quarter valued at about $352,000. Western Standard LLC bought a new stake in shares of AngioDynamics during the 2nd quarter worth approximately $5,037,000. Finally, BlackRock Inc. bought a new position in AngioDynamics in the second quarter valued at approximately $49,480,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Stock Performance

ANGO stock opened at $15.75 on Monday. AngioDynamics, Inc. has a 52-week low of $9.06 and a 52-week high of $16.29. The business has a 50-day simple moving average of $13.96 and a two-hundred day simple moving average of $12.07. The company has a market capitalization of $650.95 million, a P/E ratio of -18.10 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANGO has been the subject of a number of research reports. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright upped their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Hold” and a consensus price target of $19.50.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.00% of the stock is owned by company insiders.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.